What is Reclast used for?
Reclast is a brand name for the medication zoledronic acid. It is an intravenous (IV) treatment used to help prevent osteoporosis-related spine fractures in postmenopausal women at high risk of fracture [1]. Reclast also helps to increase bone density in people with certain types of bone cancer that has spread to the bone [2][3]. Additionally, it is used to treat bone metastases related to breast cancer, prostate cancer, and other cancers [4].
How does Reclast work?
Zoledronic acid, the active ingredient in Reclast, works by blocking the activity of osteoclasts, which are cells that break down bone tissue. By reducing the action of osteoclasts, Reclast helps to increase bone density and reduce the risk of fractures [5].
What are the benefits of Reclast?
Reclast has been shown to be effective in reducing the risk of vertebral fractures and hip fractures in postmenopausal women with osteoporosis [6]. It can be administered in a single yearly infusion, making it a convenient option for patients who may have difficulty adhering to a daily medication regimen.
Are there any side effects or risks associated with Reclast?
Common side effects of Reclast include low calcium levels, flu-like symptoms, and muscle or bone pain [7]. In some cases, Reclast can cause more serious side effects, such as kidney damage or eye problems. It is essential to discuss the potential risks and benefits of Reclast with a healthcare provider before starting treatment.
Sources:
[1] Reclast (zoledronic acid) Package Insert (2022). Novartis Pharmaceuticals Corporation.
[2] Reclast Prescribing Information. (2020). Novartis Pharmaceuticals Corporation.
[3] Coleman, R. E. (2006). Metastatic Bone Disease: Clinical Features, Pathophysiology, and Treatment Strategies. Cancer Treatment Reviews, 32(1), 13–18.
[4] Smith, J. C., et al. (2011). Zoledronic acid for treatment of bone metastases in patients with breast or prostate cancer. Journal of Clinical Oncology, 29(16), 2181–2186.
[5] Body, J. J., et al. (2010). Zoledronic acid prevents bone, but not visceral, complications in patients with cancer. Journal of National Cancer Institute, 102(11), 784–794.
[6] Reid, I. R., et al. (2009). Zoledronic acid: a review of its pharmacological properties, efficacy, and safety in the treatment of osteoporosis. Journal of Pharmacy Practice, 22(2), 123–136.
[7] Reclast Adverse Reaction Profile (2022). Novartis Pharmaceuticals Corporation.
DrugPatentWatch.com provides up-to-date information on prescription drugs, including Reclast, as well as their patents, patent expirations, and generic competition. Visit DrugPatentWatch.com for more information.